NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/25/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization11.86 mln
Earnings Date08/14/2026
EPS
14.59
Robust
P / E
0.04
Anomalous
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
18.33
Transformational upside
Relative Strength
98
/ 100
Top performer
Debt / Equity
0.02
Debt-free
Business Description
Moleculin Biotech is a Houston-based pharmaceutical company focused on developing treatments for cancer and viral diseases. Its most advanced drug, Annamycin, is currently in clinical trials for certain forms of leukemia and lung tumors. The company is also working on two additional drug families ? one aimed at disrupting the signaling processes that allow brain, pancreatic, and other cancers to grow, and another designed to cut off the energy supply that tumors depend on to survive.
